RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0041-1731427
Gastric Neuroendocrine Tumor
Funding None.
Abstract
Gastric neuroendocrine tumor (gNET) is a rare carcinoid of the stomach whose incidence is increasing due to widespread use of upper gastrointestinal endoscopy (UGIE). There are four types of gNETs with different management strategies and prognosis. Here, we present a patient who came with abdomen pain and intermittent melena. UGIE showed a sessile polyp in the stomach. The patient subsequently underwent polypectomy and was symptomatically relieved.
Ethics Approval and Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Availability of Data and Materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publikationsverlauf
Eingereicht: 11. Dezember 2020
Angenommen: 31. März 2021
Artikel online veröffentlicht:
19. Juli 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Kwon DH, Nakakura EK, Bergsland EK, Dai SC. Gastric neuroendocrine tumors: management and challenges. Gastrointestinal Cancer: Targets and Therapy 2017; 29 (07) 31-37
- 2 Dias AR, Azevedo BC, Alban LBV. et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig 2017; 30 (02) 150-154
- 3 Lupinacci RM, Dias AR, Mello ES, Kondo A. Minute type I gastric carcinoid with regional lymph node metastasis. Int J Surg Pathol 2013; 21 (02) 169-172
- 4 Fossmark R, Sørdal Ø, Jianu CS. et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012; 36 (11-12): 1067-1075
- 5 Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract 2012; 2012: 287825
- 6 Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009; 104 (06) 1524-1532
- 7 Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features, and treatment of gastric neuroendocrine tumors. World J Gastroenterol 2014; 20 (01) 118-125
- 8 Namikawa T, Oki T, Kitagawa H, Okabayashi T, Kobayashi M, Hanazaki K. Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation. Med Mol Morphol 2013; 46 (01) 34-40
- 9 Gonzalez HH, Acosta M, Yazji G, Bromer MQ. Type 1 gastric neuroendocrine tumor found on endoscopic polypectomy. Cureus 2019; 11 (03) e4193
- 10 Grozinsky-Glasberg S, Kaltsas G, Gur C. et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159 (04) 475-482
- 11 Gupta S, Johnson MM, Murthy R. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
- 12 Breeman WA, de Jong M, Kwekkeboom DJ. et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations, and future perspectives. Eur J Nucl Med 2001; 28 (09) 1421-1429